The FDA has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for Opdivo and Yervoy ...

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as a first-line therapy for patients with a ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...

Bristol Myers said about 5% to 7% of people with metastatic colorectal cancer have microsatellite instability-high or mismatch-repair-deficient tumors, adding that these patients are less likely to ...

Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...

Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) ...

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

Bristol-Myers saw its share prices grow by 3.67 percent on Monday to finish at $57.88 apiece as investors cheered news of the ...

Opdivo plus Cometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.

The application was based on results from the three-arm Phase 3 CheckMate -8HW study.